Naoto T Ueno

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. pmc A link between mir-100 and FRAP1/mTOR in clear cell ovarian cancer
    Ankur K Nagaraja
    Department of Pathology, Baylor College of Medicine, Houston, Texas 77030, USA
    Mol Endocrinol 24:447-63. 2010
  2. pmc Tumour response interpretation with new tumour response criteria vs the World Health Organisation criteria in patients with bone-only metastatic breast cancer
    T Hamaoka
    Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M D Anderson Cancer Center, Houston, 77030, USA
    Br J Cancer 102:651-7. 2010
  3. pmc Targeting EGFR in Triple Negative Breast Cancer
    Naoto T Ueno
    1 Breast Cancer Translational Research Laboratory, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    J Cancer 2:324-8. 2011
  4. pmc Gemcitabine Overcomes Erlotinib Resistance in EGFR-Overexpressing Cancer Cells through Downregulation of Akt
    Chandra Bartholomeusz
    1 Breast Cancer Translational Research Laboratory, The University of Texas MD Anderson Cancer Center, Houston, Texas
    J Cancer 2:435-42. 2011
  5. pmc The Role of F-FDG-Positron Emission Tomography/Computed Tomography in Staging Primary Breast Cancer
    Naoki Niikura
    Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    J Cancer 1:51-3. 2010
  6. pmc Addition of GM-CSF to trastuzumab stabilises disease in trastuzumab-resistant HER2+ metastatic breast cancer patients
    Y C Cheng
    Division of Neoplastic Diseases and Related Disorders, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA
    Br J Cancer 103:1331-4. 2010
  7. pmc 4th Edition of the International Autologous and Allogeneic Cell Therapy for Solid Tumors (ATST) Meeting
    Marco Bregni
    1 Department of Hematology, Istituto Scientifico San Raffaele, Milano, Italy
    J Cancer 2:307-8. 2011
  8. pmc Phase II study of gonadotropin-releasing hormone analog for ovarian function preservation in hematopoietic stem cell transplantation patients
    Yee Chung Cheng
    Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA
    Oncologist 17:233-8. 2012
  9. pmc Prediction of paclitaxel sensitivity by CDK1 and CDK2 activity in human breast cancer cells
    Satoshi Nakayama
    Central Research Laboratories, Sysmex Corporation, 4 4 4, Takatsukadai, Nishi ku, Kobe, Japan
    Breast Cancer Res 11:R12. 2009
  10. doi request reprint ABC conceptual model of effective multidisciplinary cancer care
    Naoto T Ueno
    Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77098, USA
    Nat Rev Clin Oncol 7:544-7. 2010

Collaborators

Detail Information

Publications119 found, 100 shown here

  1. pmc A link between mir-100 and FRAP1/mTOR in clear cell ovarian cancer
    Ankur K Nagaraja
    Department of Pathology, Baylor College of Medicine, Houston, Texas 77030, USA
    Mol Endocrinol 24:447-63. 2010
    ....
  2. pmc Tumour response interpretation with new tumour response criteria vs the World Health Organisation criteria in patients with bone-only metastatic breast cancer
    T Hamaoka
    Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M D Anderson Cancer Center, Houston, 77030, USA
    Br J Cancer 102:651-7. 2010
    ....
  3. pmc Targeting EGFR in Triple Negative Breast Cancer
    Naoto T Ueno
    1 Breast Cancer Translational Research Laboratory, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    J Cancer 2:324-8. 2011
    ....
  4. pmc Gemcitabine Overcomes Erlotinib Resistance in EGFR-Overexpressing Cancer Cells through Downregulation of Akt
    Chandra Bartholomeusz
    1 Breast Cancer Translational Research Laboratory, The University of Texas MD Anderson Cancer Center, Houston, Texas
    J Cancer 2:435-42. 2011
    ..Our data show that gemcitabine increased the cytotoxic effect of erlotinib by downregulating p-Akt in EGFR-overexpressing cells with either intrinsic or acquired erlotinib resistance...
  5. pmc The Role of F-FDG-Positron Emission Tomography/Computed Tomography in Staging Primary Breast Cancer
    Naoki Niikura
    Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    J Cancer 1:51-3. 2010
    ..We discuss studies comparing PET/CT with conventional imaging for diagnosing distant metastases and axillary and extra-axillary lymph node metastases...
  6. pmc Addition of GM-CSF to trastuzumab stabilises disease in trastuzumab-resistant HER2+ metastatic breast cancer patients
    Y C Cheng
    Division of Neoplastic Diseases and Related Disorders, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA
    Br J Cancer 103:1331-4. 2010
    ..Granulocyte-macrophage colony-stimulating factor (GM-CSF) mediates ADCC. We presented our pilot study of adding GM-CSF to trastuzumab in patients with trastuzumab-resistant HER2+ metastatic breast cancer...
  7. pmc 4th Edition of the International Autologous and Allogeneic Cell Therapy for Solid Tumors (ATST) Meeting
    Marco Bregni
    1 Department of Hematology, Istituto Scientifico San Raffaele, Milano, Italy
    J Cancer 2:307-8. 2011
    ..The fourth edition of the International Autologous and Allogeneic Cell Therapy for Solid Tumors (ATST) meeting was held in Venice, Italy, between March 31 and April 1, 2011...
  8. pmc Phase II study of gonadotropin-releasing hormone analog for ovarian function preservation in hematopoietic stem cell transplantation patients
    Yee Chung Cheng
    Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, Wisconsin, USA
    Oncologist 17:233-8. 2012
    ..We conducted a phase II clinical trial based on the hypothesis that giving leuprolide before conditioning chemotherapy in HSCT patients reduces premature ovarian failure incidence...
  9. pmc Prediction of paclitaxel sensitivity by CDK1 and CDK2 activity in human breast cancer cells
    Satoshi Nakayama
    Central Research Laboratories, Sysmex Corporation, 4 4 4, Takatsukadai, Nishi ku, Kobe, Japan
    Breast Cancer Res 11:R12. 2009
    ..We hypothesized that cyclin-dependent kinase (CDK) 1 activity and CDK2 activity in cancer cells, which reflect the activation state of the spindle assembly checkpoint and the growth state, respectively, predict sensitivity to paclitaxel...
  10. doi request reprint ABC conceptual model of effective multidisciplinary cancer care
    Naoto T Ueno
    Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77098, USA
    Nat Rev Clin Oncol 7:544-7. 2010
    ..Teams trained in the ABC model should better understand the function and importance of each member's role, increase patient involvement and satisfaction with treatment, and ultimately improve patient outcomes...
  11. ncbi request reprint E1A: tumor suppressor or oncogene? Preclinical and clinical investigations of E1A gene therapy
    N T Ueno
    Department of Molecualr and Cellular Oncology, The University of Texas, M D Anderson Cancer Center, 1515 Holcombe Boulevard, Box 448, Houston, TX 77030, USA
    Breast Cancer 8:285-93. 2001
    ..In this chapter, we recount our development of E1A as a therapeutic gene...
  12. ncbi request reprint High-dose chemotherapy and autologous peripheral blood stem cell transplantation for primary breast cancer refractory to neoadjuvant chemotherapy
    N T Ueno
    Department of Blood and Marrow Transplantation, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Bone Marrow Transplant 37:929-35. 2006
    ..Both OS and PFS were better in patients whose disease became operable after chemotherapy than in those whose disease remained inoperable. A randomized study is warranted in this patient population...
  13. ncbi request reprint What's past is prologue: lessons learned and the need for further development of allogeneic hematopoietic stem cell transplantation for renal cell carcinoma
    Naoto T Ueno
    Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Biol Blood Marrow Transplant 13:31-3. 2007
  14. doi request reprint Pilot study of targeted skeletal radiation therapy for bone-only metastatic breast cancer
    Naoto T Ueno
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Clin Breast Cancer 9:173-7. 2009
    ..This pilot study was designed to determine the safety and efficacy of (166)Holmium (Ho)-DOTMP for irradiating malignant cells and adjacent marrow in women with bone-only metastatic breast cancer...
  15. ncbi request reprint Rapid induction of complete donor chimerism by the use of a reduced-intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem cell transplantation for metastatic solid tumors
    Naoto T Ueno
    Department of Blood and Marrow Transplantation, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 448, Houston, TX 77030, USA
    Blood 102:3829-36. 2003
    ..It induces rapid complete donor chimerism without the need for donor lymphocyte infusion. Tumor regression associated with GVHD is consistent with graft-versus-tumor effect...
  16. ncbi request reprint Successful non-myeloablative allogeneic transplantation for treatment of idiopathic hypereosinophilic syndrome
    Naoto T Ueno
    Department of Blood and Marrow Transplantation, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Br J Haematol 119:131-4. 2002
    ..This report provides proof of principle for the feasibility of non-myeloablative transplantation for patients with idiopathic HES, who can show co-morbidity due to eosinophilic infiltration of their organs...
  17. doi request reprint PEA-15 inhibits tumorigenesis in an MDA-MB-468 triple-negative breast cancer xenograft model through increased cytoplasmic localization of activated extracellular signal-regulated kinase
    Chandra Bartholomeusz
    Breast Cancer Translational Research Laboratory, Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 16:1802-11. 2010
    ..To determine the role of PEA-15 in breast cancer...
  18. pmc Epidermal growth factor receptor tyrosine kinase inhibitor reverses mesenchymal to epithelial phenotype and inhibits metastasis in inflammatory breast cancer
    Dongwei Zhang
    Breast Cancer Translational Research Laboratory, Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Clin Cancer Res 15:6639-48. 2009
    ..Epidermal growth factor receptor (EGFR) expression is an independent poor prognostic factor in IBC. The purpose of this study was to determine the effect on IBC tumorigenicity and metastasis of blocking the EGFR pathway...
  19. ncbi request reprint Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab
    Issa F Khouri
    Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Blood 111:5530-6. 2008
    ..Only 5 patients were still undergoing immunosuppressive therapy at the time of last follow-up. We believe that the described results are a step forward toward developing a curative strategy for recurrent follicular lymphoma...
  20. pmc MEK1/2 inhibitor selumetinib (AZD6244) inhibits growth of ovarian clear cell carcinoma in a PEA-15-dependent manner in a mouse xenograft model
    Chandra Bartholomeusz
    Breast Cancer Translational Research Laboratory, University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Mol Cancer Ther 11:360-9. 2012
    ..Our findings indicate that the MEK-ERK pathway is a potential target for EGFR-overexpressing CCC and indicate that selumetinib and erlotinib are worth exploring as therapeutic agents for CCC...
  21. pmc Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors
    Naoki Niikura
    The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 1354, Houston, TX 77030, USA
    J Clin Oncol 30:593-9. 2012
    ..We also compared the overall survival durations of patients with HER2-concordant and -discordant tumors...
  22. pmc A prospective study of bone tumor response assessment in metastatic breast cancer
    Naoki Hayashi
    Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Clin Breast Cancer 13:24-30. 2013
    ..In this pilot study, we tested whether MDA criteria could reveal bone metastasis response earlier than WHO criteria in patients with newly diagnosed breast cancer with osseous and measurable nonosseous metastases...
  23. pmc Sensitivity of breast cancer cells to erlotinib depends on cyclin-dependent kinase 2 activity
    Fumiyuki Yamasaki
    Breast Cancer Translational Research Laboratory, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 448, Houston, TX 77030 4009, USA
    Mol Cancer Ther 6:2168-77. 2007
    ....
  24. doi request reprint 18F-FDG PET/CT findings and circulating tumor cell counts in the monitoring of systemic therapies for bone metastases from breast cancer
    Ugo De Giorgi
    Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    J Nucl Med 51:1213-8. 2010
    ..Our objective was to compare the predictive significance of (18)F-FDG PET/CT findings and circulating tumor cell (CTC) count in patients with bone metastases from breast cancer treated with standard systemic therapy...
  25. ncbi request reprint The use of high-dose cyclophosphamide, carmustine, and thiotepa plus autologous hematopoietic stem cell transplantation as consolidation therapy for high-risk primary breast cancer after primary surgery or neoadjuvant chemotherapy
    Yee Chung Cheng
    Department of Blood and Marrow Transplantation, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Biol Blood Marrow Transplant 10:794-804. 2004
    ..In accordance with results from recent randomized studies, we need to continue high-dose chemotherapy with AHST for patients with high-risk primary breast cancer in the phase III randomized setting...
  26. ncbi request reprint Adenovirus type 5 E1A gene therapy for ovarian clear cell carcinoma: a potential treatment strategy
    Hiroaki Itamochi
    Department of Stem Cell Transplantation and Cellular Therapy, Unit 448, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Mol Cancer Ther 6:227-35. 2007
    ..001). E1A gene therapy, because of its ability to stabilize wild-type p53, is worth exploring as a treatment modality for women with ovarian CCC, which typically expresses wild-type p53...
  27. doi request reprint Relationship between lymphocytopenia and circulating tumor cells as prognostic factors for overall survival in metastatic breast cancer
    Ugo De Giorgi
    Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Clin Breast Cancer 12:264-9. 2012
    ....
  28. pmc Initial staging impact of fluorodeoxyglucose positron emission tomography/computed tomography in locally advanced breast cancer
    Naoki Niikura
    Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Oncologist 16:772-82. 2011
    ..We hypothesized that patients diagnosed with stage III noninflammatory breast cancer (non-IBC) and IBC by conventional imaging with PET/CT have a better prognosis than patients diagnosed without PET/CT...
  29. ncbi request reprint Interleukin-2 and granulocyte-macrophage-colony-stimulating factor immunomodulation with high-dose chemotherapy and autologous hematopoietic stem cell transplantation for patients with metastatic breast cancer
    Yee Chung Cheng
    Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Int J Hematol 90:627-34. 2009
    ..Estimated 3-year progression-free and overall survival rates were 31 and 57%. Our study suggested that the use of IL-2 and growth factors immunomodulation with HDC/AHST was feasible with comparable survival rates...
  30. pmc Prognostic value of HER2-positive circulating tumor cells in patients with metastatic breast cancer
    Naoki Hayashi
    Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Int J Clin Oncol 17:96-104. 2012
    ..The presence of ≥5 circulating tumor cells (CTCs) in 7.5 ml blood is a poor prognostic marker in metastatic breast cancer (MBC). However, the role of human epidermal growth factor receptor 2 (HER2) status in CTCs is not known...
  31. ncbi request reprint Inflammatory breast cancer (IBC) and patterns of recurrence: understanding the biology of a unique disease
    Massimo Cristofanilli
    Department of Breast Medical Oncology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 110:1436-44. 2007
    ..The authors compared the prognostic features of IBC and non-IBC locally advanced breast cancer (LABC) to gain insight into the biology of this disease entity...
  32. pmc Epithelial-mesenchymal transition and stem cell markers in patients with HER2-positive metastatic breast cancer
    Antonio Giordano
    Department of Hematopathology, Unit 0054, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, 77030, Houston, TX, USA
    Mol Cancer Ther 11:2526-34. 2012
    ..Moreover, an enrichment of CSCs was found in CD326(-)CD45(-) cells. Additional studies are needed to determine whether EMT-CTCs and CSCs have prognostic value in patients with HER2(+) MBCs treated with trastuzumab-based therapy...
  33. doi request reprint Pretreatment staging positron emission tomography/computed tomography in patients with inflammatory breast cancer influences radiation treatment field designs
    Gary V Walker
    Department of Radiation Oncology, The Morgan Welch Inflammatory Breast Cancer Clinic, University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    Int J Radiat Oncol Biol Phys 83:1381-6. 2012
    ..The purpose of this study was to define how pretreatment PET/CT studies affected postmastectomy radiation treatment (PMRT) planning decisions for IBC...
  34. pmc Serum HER2 levels determined by two methods in patients with metastatic breast cancer
    Naoki Hayashi
    Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Int J Clin Oncol 17:55-62. 2012
    ..We prospectively assessed the prognostic value of serum HER2 levels in MBC using two methods, enzyme immunoassay (EIA) and chemiluminescence immunoassay (CLIA)...
  35. pmc FDG-PET/CT compared with conventional imaging in the detection of distant metastases of primary breast cancer
    Naoki Niikura
    Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Oncologist 16:1111-9. 2011
    ..We compared the sensitivity and specificity of PET/CT and conventional imaging (CT, ultrasonography, radiography, and skeletal scintigraphy) for the detection of distant metastases in patients with primary breast cancer...
  36. pmc Activity of lapatinib is independent of EGFR expression level in HER2-overexpressing breast cancer cells
    Dongwei Zhang
    Department of Breast Medical Oncology, Unit 1354, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Mol Cancer Ther 7:1846-50. 2008
    ..We conclude that the in vitro activity of lapatinib is not dependent on EGFR expression level in HER2-overexpressing breast cancer cells...
  37. pmc Silencing kinase-interacting stathmin gene enhances erlotinib sensitivity by inhibiting Ser¹⁰ p27 phosphorylation in epidermal growth factor receptor-expressing breast cancer
    Dongwei Zhang
    Breast Cancer Translational Research Laboratory, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Mol Cancer Ther 9:3090-9. 2010
    ..Our study provides a rationale for the development of combinations of erlotinib with KIS inhibition to overcome EGFR TKI resistance in EGFR-expressing breast cancer...
  38. ncbi request reprint Targeting p70S6K prevented lung metastasis in a breast cancer xenograft model
    Ugur Akar
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Mol Cancer Ther 9:1180-7. 2010
    ....
  39. ncbi request reprint Acquired resistance to erlotinib in A-431 epidermoid cancer cells requires down-regulation of MMAC1/PTEN and up-regulation of phosphorylated Akt
    Fumiyuki Yamasaki
    Breast Cancer Translational Research Laboratory, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Cancer Res 67:5779-88. 2007
    ..We propose that acquired erlotinib resistance associated with MMAC1/PTEN down-regulation and Akt activation could be overcome by inhibitors of signaling through the phosphatidylinositol 3-kinase pathway...
  40. doi request reprint Polycomb group protein EZH2 is frequently expressed in inflammatory breast cancer and is predictive of worse clinical outcome
    Yun Gong
    Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 117:5476-84. 2011
    ..In this retrospective study, the authors examined EZH2 expression in IBC tumors and evaluated the relation between EZH2 expression and patient survival...
  41. pmc The antihelmintic drug pyrvinium pamoate targets aggressive breast cancer
    Wei Xu
    Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America
    PLoS ONE 8:e71508. 2013
    ..These findings suggest WNT signaling inhibition may be a feasible strategy for targeting aggressive breast cancer. Investigation and modification of the bioavailability and toxicity profile of systemic PP are warranted. ..
  42. ncbi request reprint Cyclin A-associated kinase activity is needed for paclitaxel sensitivity
    Takeshi Takahashi
    Department of Blood and Marrow Transplantation, Unit 448, The University of Texas M D Anderson Cancer Center, Houston, 77030, USA
    Mol Cancer Ther 4:1039-46. 2005
    ..Combining taxane chemotherapy with any drug targeting cyclin A-associated kinases (e.g., pure CDK2 inhibitors) should be done with caution, if at all, because of the potential for enhancing taxane resistance...
  43. pmc Bisphosphorylated PEA-15 sensitizes ovarian cancer cells to paclitaxel by impairing the microtubule-destabilizing effect of SCLIP
    Xuemei Xie
    Section of Translational Breast Cancer Research, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Mol Cancer Ther 12:1099-111. 2013
    ..Our findings highlight the importance of pPEA-15 as a promising target for improving the efficacy of paclitaxel-based therapy in ovarian cancer...
  44. ncbi request reprint Predicting outcome based on Swenerton score in patients with metastatic breast cancer undergoing high-dose chemotherapy and autologous hematopoietic stem cell transplantation: implications for patient selection
    Filippo Montemurro
    Department of Blood and Marrow Transplantation, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Biol Blood Marrow Transplant 9:330-40. 2003
    ..01). The Swenerton score provides a thorough estimate of disease extent, and reduction of Swenerton score by SDCT is potentially useful for selecting the optimal candidates for HDCT trials who may achieve long-term disease control...
  45. pmc Treatment outcome and prognostic factors for patients with bone-only metastases of breast cancer: a single-institution retrospective analysis
    Naoki Niikura
    Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 1354, Houston, Texas 77030, USA
    Oncologist 16:155-64. 2011
    ....
  46. doi request reprint TIG1 promotes the development and progression of inflammatory breast cancer through activation of Axl kinase
    Xiaoping Wang
    Authors Affiliations Department of Breast Medical Oncology, Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, Departments of Molecular and Cellular Oncology, Pathology, Radiation Oncology, and Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas Tolero Pharmaceuticals, Inc, Salt Lake City, Utah and Center for Molecular Medicine and Graduate Institute of Cancer Biology, China Medical University, Taichung, Taiwan
    Cancer Res 73:6516-25. 2013
    ..Our findings establish that TIG1 positively modifies the malignant properties of IBC by supporting Axl function, advancing understanding of its development and rationalizing TIG1 and Axl as promising therapeutic targets in IBC treatment...
  47. ncbi request reprint [Allogeneic hematopoietic stem cell transplantation for solid tumors in the United States: a review]
    Yee Chung Cheng
    Departments of Blood and Marrow Transplantation, Breast Cancer Research Program, University of Texas M D Anderson Cancer Center, USA
    Nihon Rinsho 61:1619-34. 2003
    ..This review summarizes the peer-reviewed literature on the use of allogeneic transplantation for solid tumors based on US studies...
  48. pmc Inflammatory breast cancer: what we know and what we need to learn
    Hideko Yamauchi
    Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Oncologist 17:891-9. 2012
    ..We review the current status of multidisciplinary care for patients with inflammatory breast cancer (IBC) and discuss what further research is needed to advance the care of patients with this disease...
  49. doi request reprint Histone deacetylase inhibitors stimulate dedifferentiation of human breast cancer cells through WNT/β-catenin signaling
    Bisrat G Debeb
    Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Stem Cells 30:2366-77. 2012
    ..These results demonstrate that HDAC inhibitors promote the expansion of breast CSCs through dedifferentiation and have important clinical implications for the use of HDAC inhibitors in the treatment of cancer...
  50. pmc Retrospective analysis of antitumor effects of zoledronic acid in breast cancer patients with bone-only metastases
    Naoki Niikura
    Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    Cancer 118:2039-47. 2012
    ....
  51. ncbi request reprint Natural history of metastatic renal cell carcinoma in patients who underwent consultation for allogeneic hematopoietic stem cell transplantation
    Kazutaka Nakayama
    Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Biol Blood Marrow Transplant 13:975-85. 2007
    ..The role of allogeneic HSCT for patients with no prognostic factors should be explored in clinical trials for patients with targeted therapy-resistant metastatic RCC...
  52. pmc Improvement of survival and prospect of cure in patients with metastatic breast cancer
    Yee Chung Cheng
    Division of Hematology and Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA
    Breast Cancer 19:191-9. 2012
    ..Whether patients with prolonged disease control are "cured" remains controversial...
  53. doi request reprint Characterization of metastatic breast cancer patients with nondetectable circulating tumor cells
    Michal Mego
    Departments of Hematopathology, The Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, University of Texas, MD Anderson Cancer Center, Houston, TX, USA
    Int J Cancer 129:417-23. 2011
    ..We showed that some important metastatic disease characteristics are predictive of undetectable CTC status in MBC...
  54. doi request reprint Differences in survival among women with stage III inflammatory and noninflammatory locally advanced breast cancer appear early: a large population-based study
    Shaheenah Dawood
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Cancer 117:1819-26. 2011
    ....
  55. pmc PEA-15 induces autophagy in human ovarian cancer cells and is associated with prolonged overall survival
    Chandra Bartholomeusz
    Breast Cancer Translational Research Laboratory, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Res 68:9302-10. 2008
    ..973; P = 0.0167). Our findings indicate that PEA-15 expression is an important prognostic marker in ovarian cancer...
  56. ncbi request reprint Inflammatory breast cancer: the disease, the biology, the treatment
    Fredika M Robertson
    Department of Experimental Therapeutics, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    CA Cancer J Clin 60:351-75. 2010
    ..This review examines IBC's unique clinical presentation, pathology, epidemiology, imaging, and biology and details current multidisciplinary management of the disease, which comprises systemic therapy, surgery, and radiation therapy...
  57. ncbi request reprint Receiving information on fertility- and menopause-related treatment effects among women who undergo hematopoietic stem cell transplantation: changes in perceived importance over time
    Kazutaka Nakayama
    Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Biol Blood Marrow Transplant 15:1465-74. 2009
    ..Such counseling is crucial for patients who are young and childless...
  58. ncbi request reprint Bcl-2 antisense oligonucleotide overcomes resistance to E1A gene therapy in a low HER2-expressing ovarian cancer xenograft model
    Chandra Bartholomeusz
    Breast Cancer Translational Research Laboratory, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Cancer Res 65:8406-13. 2005
    ..001). In conclusion, ovarian tumors overexpressing Bcl-2 may not respond well to E1A gene therapy, but treatment with a combination of E1A and Bcl-2-ASO may overcome this resistance...
  59. pmc Characterizing cancer cells with cancer stem cell-like features in 293T human embryonic kidney cells
    Bisrat G Debeb
    Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Mol Cancer 9:180. 2010
    ..Herein we fully characterize cancer stem cell-like features in 293T human embryonic kidney cells...
  60. pmc Adenovirus type 5 E1A-induced apoptosis in COX-2-overexpressing breast cancer cells
    Takeshi Sugimoto
    Breast Cancer Translational Research Laboratory, The University of Texas M, d, Anderson Cancer Center, Houston, TX, USA
    Breast Cancer Res 9:R41. 2007
    ..We hypothesized that celecoxib would enhance E1A-induced apoptosis by suppressing Bcl-2 through suppressing COX-2 expression. If successful, this strategy could represent a means of overcoming resistance to E1A gene therapy...
  61. pmc High serum miR-19a levels are associated with inflammatory breast cancer and are predictive of favorable clinical outcome in patients with metastatic HER2+ inflammatory breast cancer
    Simone Anfossi
    Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America The University of Texas Graduate School of Biomedical Sciences at Houston, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America Morgan Welch Inflammatory Breast Cancer Research Program and Clinic, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America
    PLoS ONE 9:e83113. 2014
    ....
  62. ncbi request reprint Novel mechanism of reduced proliferation in ovarian clear cell carcinoma cells: cytoplasmic sequestration of CDK2 by p27
    Hiroaki Itamochi
    Breast Cancer Translational Research Laboratory, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Gynecol Oncol 122:641-7. 2011
    ..We previously found an association between reduced proliferation of CCC and chemoresistance; here we investigated the mechanism of the reduced proliferation...
  63. ncbi request reprint Nonmyeloablative allogeneic hematopoietic transplantation: a promising salvage therapy for patients with non-Hodgkin's lymphoma whose disease has failed a prior autologous transplantation
    Maricer P Escalon
    Department of Blood and Marrow Transplantation, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 22:2419-23. 2004
    ..We investigated the safety and efficacy of nonmyeloablative stem-cell transplantation in these patients...
  64. doi request reprint Estrogen receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1% to 10% ER-positive by immunohistochemistry
    Takayuki Iwamoto
    The University of Texas MD Anderson Cancer Center, Houston, TX 77230 1439, USA
    J Clin Oncol 30:729-34. 2012
    ....
  65. pmc Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment
    Mario Giuliano
    Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, 77030, USA
    Breast Cancer Res 13:R67. 2011
    ..We assessed the prognostic impact of CTCs according to different first-line systemic treatments, and explored their potential predictive value in MBC patients...
  66. pmc Prognostic impact of phosphorylated HER-2 in HER-2+ primary breast cancer
    Naoki Hayashi
    Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Oncologist 16:956-65. 2011
    ..We determined the prognostic value of the expression level of tyrosine 1248-phosphorylated HER-2 (pHER-2) in patients with HER-2(+) primary breast cancer using a reverse-phase protein array...
  67. doi request reprint Circulating tumor cells and [18F]fluorodeoxyglucose positron emission tomography/computed tomography for outcome prediction in metastatic breast cancer
    Ugo De Giorgi
    The University of Texas M D Anderson Cancer Center, Houston, 77030, USA
    J Clin Oncol 27:3303-11. 2009
    ..In this study, we compared the prognostic value of CTC and FDG-PET/CT monitoring during systemic therapy for metastatic breast cancer (MBC)...
  68. doi request reprint High-dose chemotherapy with autologous stem-cell support as adjuvant therapy in breast cancer: overview of 15 randomized trials
    Donald A Berry
    Division of Quantitative Sciences, Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX 77230 1402, USA
    J Clin Oncol 29:3214-23. 2011
    ..Individual trials have had limited power to show overall benefit or benefits within subsets...
  69. ncbi request reprint B cell translocation gene 1 contributes to antisense Bcl-2-mediated apoptosis in breast cancer cells
    Rita Nahta
    Department of Breast Medical Oncology, Unit 1354, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030 4009, USA
    Mol Cancer Ther 5:1593-601. 2006
    ..These results suggest that BTG1 is a Bcl-2-regulated mediator of apoptosis in breast cancer cells, and that its induction contributes to antisense Bcl-2-mediated cytotoxic effects...
  70. pmc Adding hormonal therapy to chemotherapy and trastuzumab improves prognosis in patients with hormone receptor-positive and human epidermal growth factor receptor 2-positive primary breast cancer
    Naoki Hayashi
    Department of Breast Medical Oncology, Unit 1354, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Breast Cancer Res Treat 137:523-31. 2013
    ..Adjuvant treatment without hormonal therapy is inferior for this patient population...
  71. pmc Different gene expressions are associated with the different molecular subtypes of inflammatory breast cancer
    Takayuki Iwamoto
    Breast Cancer Translational Research Laboratory, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Breast Cancer Res Treat 125:785-95. 2011
    ..IBC tumors can be divided into molecular and clinical subtypes similar to those of non-IBC. Clinical subtypes of IBC show molecular differences compared with similar subtypes of non-IBC...
  72. pmc Triple-negative subtype predicts poor overall survival and high locoregional relapse in inflammatory breast cancer
    Jing Li
    Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Oncologist 16:1675-83. 2011
    ..However, these findings have not been confirmed for inflammatory breast cancer (IBC), which has different biological features than non-IBC...
  73. ncbi request reprint P27(kip1) down-regulation is associated with trastuzumab resistance in breast cancer cells
    Rita Nahta
    Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Cancer Res 64:3981-6. 2004
    ..Thus, we propose that trastuzumab resistance may be associated with decreased p27(kip1) levels and may be susceptible to treatments that induce p27(kip1) expression...
  74. ncbi request reprint Imaging bone metastases in breast cancer: techniques and recommendations for diagnosis
    Colleen M Costelloe
    Breast Cancer Bone Working Group and Department of Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Lancet Oncol 10:606-14. 2009
    ..The imaging method used in non-emergent situations, such as assessment of the ribs, sternum, pelvis, hips, and joints, should be guided by the strengths and limitations of each technique...
  75. ncbi request reprint Allogeneic hematopoietic cell transplantation for metastatic breast cancer
    N T Ueno
    The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Bone Marrow Transplant 41:537-45. 2008
    ..These findings support the need for preclinical and clinical studies that facilitate targeted adoptive immunotherapy for breast cancer to explore the benefit of a GVT effect in breast cancer...
  76. pmc Role of epidermal growth factor receptor in breast cancer
    Hiroko Masuda
    Department of Breast Medical Oncology, Unit 1354, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Breast Cancer Res Treat 136:331-45. 2012
    ..Further studies of the role of EGFR in TNBC and IBC are needed to better understand the best way to use EGFR-targeted therapy-e.g., as a chemosensitizer or to prevent metastases-to treat these aggressive diseases...
  77. doi request reprint Chromosome 17 polysomy in circulating tumor cells in patients with metastatic breast cancer: a case series
    Naoki Hayashi
    Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Int J Clin Oncol 16:596-600. 2011
    ..In summary, polysomy 17 in CTCs was observed in only a small population of patients with MBC. We should prospectively evaluate its prognostic value in both HER2-positive and -negative metastatic breast cancer...
  78. pmc A novel hTERT promoter-driven E1A therapeutic for ovarian cancer
    Xiaoming Xie
    Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Unit 108, Houston, Texas 77030, USA
    Mol Cancer Ther 8:2375-82. 2009
    ..v. delivery of T-VISA-E1A:liposomal nanoparticles, suggesting a promising role of T-VISA-E1A for ovarian cancer treatment under a gene therapy setting...
  79. ncbi request reprint Idiopathic pneumonia syndrome after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for high-risk breast cancer
    R Wong
    Department of Blood and Marrow Transplantation, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Bone Marrow Transplant 31:1157-63. 2003
    ..Given the absence of predictive factors, any pulmonary symptoms appearing in the first year after the transplant should be evaluated carefully...
  80. pmc Differential radiosensitizing effect of valproic acid in differentiation versus self-renewal promoting culture conditions
    Bisrat G Debeb
    Division of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Int J Radiat Oncol Biol Phys 76:889-95. 2010
    ..From these data, we hypothesized that VA would fail to radiosensitize breast cancer stem/progenitor cells grown to three-dimensional (3D) mammospheres...
  81. pmc Prognostic Value of EMT-Circulating Tumor Cells in Metastatic Breast Cancer Patients Undergoing High-Dose Chemotherapy with Autologous Hematopoietic Stem Cell Transplantation
    Michal Mego
    1 Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX 7 Current Address National Cancer Institute, Klenova 1, 833 10 Bratislava, Slovak Republic
    J Cancer 3:369-80. 2012
    ..Conclusion: Our data suggest that CTC and CTCs with EMT are prognostic in MBC patients undergoing HDCT followed by AHSCT...
  82. doi request reprint High-dose chemotherapy with autologous hematopoietic stem-cell transplantation in metastatic breast cancer: overview of six randomized trials
    Donald A Berry
    Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX 77230 1402, USA
    J Clin Oncol 29:3224-31. 2011
    ....
  83. ncbi request reprint Use of thrombopoietin in combination with chemotherapy and granulocyte colony-stimulating factor for peripheral blood progenitor cell mobilization
    James L Gajewski
    University of Texas M D Anderson Cancer Center, Department of Blood and Marrow Transplantation, Houston 77030 4095, USA
    Biol Blood Marrow Transplant 8:550-6. 2002
    ..Further studies are also warranted in patients who are likely to experience suboptimal PBPC mobilization when treated with currently available techniques...
  84. ncbi request reprint Prognostic factors for outcomes of patients with refractory or relapsed acute myelogenous leukemia or myelodysplastic syndromes undergoing allogeneic progenitor cell transplantation
    Raymond Wong
    Department of Blood and Marrow Transplantation, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Biol Blood Marrow Transplant 11:108-14. 2005
    ....
  85. ncbi request reprint Allogeneic peripheral-blood progenitor-cell transplantation for poor-risk patients with metastatic breast cancer
    N T Ueno
    Department of Blood and Marrow Transplantation, University of Texas M D Anderson Cancer Center, Houston 77030, USA
    J Clin Oncol 16:986-93. 1998
    ..To evaluate the feasibility of allogeneic peripheral-blood progenitor-cell (PBPC) transplantation and to assess graft-versus-tumor effects in patients with metastatic breast cancer...
  86. doi request reprint Prolonged disease control by nonmyeloablative allogeneic transplantation for metastatic breast cancer
    J A De Souza
    Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Bone Marrow Transplant 44:81-7. 2009
    ..The question remains how to improve the overall efficacy and reduce the mortality rate for this approach...
  87. ncbi request reprint Carmustine, etoposide, cytarabine and melphalan as a preparative regimen for allogeneic transplantation for high-risk malignant lymphoma
    D Przepiorka
    Department of Blood and Marrow Transplantation, University of Texas, M D Anderson Cancer Center, Houston, USA
    Ann Oncol 10:527-32. 1999
    ....
  88. ncbi request reprint Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation
    S Giralt
    Department of Blood and Bone Marrow Transplantation and Biomathematics, University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Blood 97:631-7. 2001
    ..In summary, fludarabine/melphalan combinations are feasible in older patients with associated comorbidities, and long-term disease control can be achieved with reduced-intensity conditioning in this population...
  89. ncbi request reprint Prognostic value of nodal ratios in node-positive breast cancer
    Wendy A Woodward
    Department of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 24:2910-6. 2006
    ..Here we examine the data supporting the use of nodal ratios in breast cancer prognosis and consider the potential advantages and disadvantages of including nodal ratios in breast cancer staging...
  90. ncbi request reprint Bone imaging in metastatic breast cancer
    Tsuyoshi Hamaoka
    Breast Cancer Research Program, Department of Blood and Marrow Transplantation, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 448, Houston, TX 77030, USA
    J Clin Oncol 22:2942-53. 2004
    ....
  91. doi request reprint Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experience
    Paolo Anderlini
    The U T M D Anderson Cancer Center, Department of Stem Cell Transplantation and Cellular Therapy 1515 Holcombe Boulevard, Unit 423, Houston, TX 77030 USA
    Haematologica 93:257-64. 2008
    ..We here present an update of our single-center experience with fludarabine-melphalan as a preparative regimen...
  92. ncbi request reprint Thiotepa, busulfan, and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced myelodysplastic syndrome and acute myelogenous leukemia
    S Bibawi
    Department of Blood and Marrow Transplantation, The University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030, USA
    Am J Hematol 67:227-33. 2001
    ..TBC is an active preparative regimen for advanced AML. Patients with advanced MDS appeared to have a higher risk of toxicity and early mortality, and alternative preparative regimens should be considered for these patients...
  93. ncbi request reprint Reduced-intensity allogeneic stem cell transplantation in relapsed and refractory Hodgkin's disease: low transplant-related mortality and impact of intensity of conditioning regimen
    P Anderlini
    Department of Blood and Marrow Transplantation, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Bone Marrow Transplant 35:943-51. 2005
    ..03), and a trend towards better progression-free survival (37 vs 21% at 18 months; P=0.2). RIC allo-SCT is feasible in relapsed/refractory HD patients with a low TRM. The intensity of the preparative regimen affects survival...
  94. ncbi request reprint Thiotepa, busulfan, cyclophosphamide (TBC) and autologous hematopoietic transplantation: an intensive regimen for the treatment of multiple myeloma
    A Shimoni
    Department of Blood and Bone Marrow Transplantation, The University of Texas, MD Anderson Cancer Center, Houston, TX, USA
    Bone Marrow Transplant 27:821-8. 2001
    ..TBC merits further study in these subgroups and comparison with alternative regimens in prospective studies is warranted...
  95. ncbi request reprint Donor leukocyte infusions in relapsed Hodgkin's lymphoma following allogeneic stem cell transplantation: CD3+ cell dose, GVHD and disease response
    P Anderlini
    Department of Blood and Marrow Transplantation, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Bone Marrow Transplant 34:511-4. 2004
    ..The small sample size does not allow any conclusion as to whether chemotherapy administration increases the chance of response. The CD3 cell dose infused does not seem to correlate with disease response...
  96. ncbi request reprint Systemic gene therapy in human xenograft tumor models by liposomal delivery of the E1A gene
    Naoto T Ueno
    Breast Cancer Research Program Core Laboratory, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Res 62:6712-6. 2002
    ..Additional preclinical and clinical development of LPD-E1A is warranted for the treatment of advanced or metastatic cancer...
  97. ncbi request reprint Dependence of paclitaxel sensitivity on a functional spindle assembly checkpoint
    Tamotsu Sudo
    Breast Cancer Research Program Core Laboratory, Department of Blood and Marrow Transplantation, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Res 64:2502-8. 2004
    ..Thus, checkpoint function is required for paclitaxel sensitivity. These findings show that any molecules that could interfere with the spindle assembly checkpoint could generate paclitaxel resistance in any patient...
  98. ncbi request reprint Allogeneic hematopoietic transplantation as adoptive immunotherapy. Induction of graft-versus-malignancy as primary therapy
    R Champlin
    Department of Blood and Marrow Transplantation, University of Texas M D Anderson Cancer Center, Houston, USA
    Hematol Oncol Clin North Am 13:1041-57, vii-viii. 1999
    ....

Research Grants7

  1. Markers of sensivity to the EGFR inhibitor erlotinib in breast cancer
    Naoto Ueno; Fiscal Year: 2007
    ..Our findings will improve the outcome of cancer patients by increasing EGFR-TKI efficacy and facilitating the selection of patients who may benefit from EGFR-TKI therapy. ..
  2. Development of PEA 15 as a Targeted Therapeutic Gene for Ovarian Cancer
    Naoto Ueno; Fiscal Year: 2007
    ....
  3. Markers of sensivity to the EGFR inhibitor erlotinib in breast cancer
    Naoto Ueno; Fiscal Year: 2009
    ..Our findings will improve the outcome of cancer patients by increasing EGFR-TKI efficacy and facilitating the selection of patients who may benefit from EGFR-TKI therapy. ..
  4. Development of PEA 15 as a Targeted Therapeutic Gene for Ovarian Cancer
    Naoto Ueno; Fiscal Year: 2009
    ....
  5. Development of PEA 15 as a Targeted Therapeutic Gene for Ovarian Cancer
    Naoto T Ueno; Fiscal Year: 2010
    ....